Canary Global Inc. is a biotechnology company developing novel therapeutics and diagnostics for diseases caused by dysregulated microRNA expression. CGI is leveraging this Nobel Prize-winning discovery into an entirely new class of medicines. The company's lead product candidate is a small molecule drug that targets microRNA-21, a microRNA implicated in a wide range of diseases. Canary Global is also developing a point-of-care molecular diagnostic test that can be used to rapidly and accurately measure microRNA levels in blood or other bodily fluids.This test could be used to diagnose diseases early, monitor disease progression, and select patients for personalized therapy as well as improve the efficiency of clinical trials.

Canary Global was founded in 2020 by a team of experienced scientists and entrepreneurs. The company is committed to developing innovative therapies and diagnostics that will improve the lives of patients by leveraging the power of microRNA. Canary Global's mission is to become the leading provider of microRNA-based therapeutics and diagnostics.We are advancing a deep pipeline of innovative microRNA targeted medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) diseases.